Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Inclusion Criteria: * Male patients with a diagnosis of advanced prostate cancer for whom treatment with triptorelin pamoate or leuprolide acetate is indicated; * At least 18 years of age; * Life expectancy of at least 1 year; * Capable of completing the study questionnaires without assistance. Exclusion Criteria: * Patients for whom treatment with triptorelin pamoate or leuprolide acetate is contraindicated; * Known hypersensitivity to triptorelin, leuprolide or any other GnRH or luteinizing hormone releasing hormone (LHRH) agonists, or GnRH or LHRH; * Clinically significant systemic disease or condition that would, in the investigator's opinion, lead to undue risk following administration of either triptorelin or leuprolide; * History of alcohol/drug abuse within the past year; * History of significant medical problems that may confound the outcome of this study; * Requires concomitant medications that may affect study assessments (e.g., topical medications used for pretreatment of injection site pain); * Participated in another investigational drug study within 30 days * Judged by the investigator to be unsuitable for enrollment in this study for any reason